ArticleScientific reports2026
Exploring the effects and mechanisms of Chinese yam in treating osteoporosis using network pharmacology analysis and biological validation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chinese yam, a plant used in traditional medicine and food, shows promise for treating osteoporosis, but its exact mechanism of action remains unclear. In this study, employs network pharmacology, molecular dynamics simulation techniques, and in vitro and in vivo experiments were employed to investigate the potential mechanisms underlying the therapeutic effects of Chinese yam on osteoporosis. Our study indicates that Chinese yam primarily exerts its effects primarily through several of its active components including Phytocassane A, Batatasin II, Gibberellin, Dihydroquercetin, Garcinone D, and Diosgenin. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment revealed that the PI3K/Akt signaling pathway and MAPK signaling pathway were enriched with multiple targets, including EGFR, SRC, IL-6, AKT1, and CTNNB1. The results from molecular docking and molecular dynamics simulations revealed favourable binding stability of the target–compound complexes. Among them, Dihydroquercetin and Garcinone D demonstrated superior binding affinity for each target. In a zebrafish model demonstrated that Chinese yam extract effectively alleviated dexamethasone-induced inhibition of bone mineralization. We also found that Chinese yam extract increased alkaline phosphatase (ALP) activity, upregulated the protein expression of runt-related transcription factor 2 (RUNX2) and osteocalcin (OCN), and promoted PI3K phosphorylation in MC3T3-E1 cells treated with dexamethasone, and these effects could be reversed by a PI3K inhibitor (LY294002). This study revealed the active components and mechanisms underlying the efficacy of Chinese yam in treating osteoporosis, providing a theoretical foundation and research data for its clinical application in osteoporosis therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.